Baard Cristoffer Sakshaug
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Baard Cristoffer Sakshaug has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Christa Ringers
Norwegian University of Science and Technology 1 Department of Clinical and Molecular Medicine Trondheim, Norway
28 shared publications - Evelina Folkesson
Norwegian University of Science and Technology 1 Department of Clinical and Molecular Medicine Trondheim, Norway
28 shared publications - Geir Klinkenberg
Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway
28 shared publications - Hanne H. Trøen
Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway
28 shared publications - Henri Colyn Bwanika
Department of Oncology-Pathology, Karolinska Institutet, J6:140 BioClinicum, Solna, Sweden
28 shared publications - Ingrid A. Bergstrøm
Norwegian University of Science and Technology 1 Department of Clinical and Molecular Medicine Trondheim, Norway
28 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Material from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Detailed description of methods.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Detailed description of methods.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Sensitivity of all samples as sensitive or resistant to oxaliplatin and SN-38 using median GR50 and median AOC.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Sensitivity of all samples as sensitive or resistant to oxaliplatin and SN-38 using median GR50 and median AOC.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Classification of the eight fastest growing samples as either sensitive or resistant to oxaliplatin and SN-38 at day 7 of the experiment according to either median ED20 or median GR50.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Classification of the eight fastest growing samples as either sensitive or resistant to oxaliplatin and SN-38 at day 7 of the experiment according to either median ED20 or median GR50.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Growth rate (relative total area) of negative controls in all growing samples.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Growth rate (relative total area) of negative controls in all growing samples.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Classification of Samples 1, 3, 7, 8, 10, 12, and 13 as either sensitive or resistant to oxaliplatin and SN-38 for the total duration of the experiment, according to the median GR50 of all 16 samples on day 7 of the experiment.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Classification of Samples 1, 3, 7, 8, 10, 12, and 13 as either sensitive or resistant to oxaliplatin and SN-38 for the total duration of the experiment, according to the median GR50 of all 16 samples on day 7 of the experiment.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
A and B, Point estimates of sample library AOC. The dotted red line represents median AOC, and the blue area represents the IQR. Dot color indicates sample sensitivity according to the median, with red indicating resistant and blue indicating sensitive. C and D, Correlation plots of GR50 and AOC. The y-axis is log-transformed, and the x-axis is linear. The dotted blue line indicates the median GR50, the dotted red line indicates the median AOC, and the whole blue line indicates linear regression of log2(GR50) and AOC with CIs. GR50 is in μmol/L for oxaliplatin (left) and nmol/L for SN-38 (right).
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
A and B, Point estimates of sample library AOC. The dotted red line represents median AOC, and the blue area represents the IQR. Dot color indicates sample sensitivity according to the median, with red indicating resistant and blue indicating sensitive. C and D, Correlation plots of GR50 and AOC. The y-axis is log-transformed, and the x-axis is linear. The dotted blue line indicates the median GR50, the dotted red line indicates the median AOC, and the whole blue line indicates linear regression of log2(GR50) and AOC with CIs. GR50 is in μmol/L for oxaliplatin (left) and nmol/L for SN-38 (right).
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Dose–response curves for SN-38 generated using the log-logistic 3-parametric model fitted to either relative total area (A and B) or GR metrics (C and D). The x-axis displays drug concentration in nanomolar (nmol/L), and the y-axis displays inferred response (normalized relative total area/GR metric). Solid black line indicates the library mean inferred response across both fast- and slow-growing samples per readout, and dashed red line indicates the mean inferred response for only the fast- or slow-growing samples, respectively, per readout. Vertical red lines indicate median ED values for increasing levels of inhibition (20%, 30%, 40%, and 50%) across both fast- and slow-growing samples. A, Dose–response curves of the eight slowest-growing samples fitted to relative total area. B, Dose–response curves of the eight fastest-growing samples fitted to relative total area. C, Dose–response curves of the eight slowest-growing samples fitted to GR metrics. D, Dose–response curves of the eight fastest-growing samples fitted to GR metrics.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Dose–response curves for SN-38 generated using the log-logistic 3-parametric model fitted to either relative total area (A and B) or GR metrics (C and D). The x-axis displays drug concentration in nanomolar (nmol/L), and the y-axis displays inferred response (normalized relative total area/GR metric). Solid black line indicates the library mean inferred response across both fast- and slow-growing samples per readout, and dashed red line indicates the mean inferred response for only the fast- or slow-growing samples, respectively, per readout. Vertical red lines indicate median ED values for increasing levels of inhibition (20%, 30%, 40%, and 50%) across both fast- and slow-growing samples. A, Dose–response curves of the eight slowest-growing samples fitted to relative total area. B, Dose–response curves of the eight fastest-growing samples fitted to relative total area. C, Dose–response curves of the eight slowest-growing samples fitted to GR metrics. D, Dose–response curves of the eight fastest-growing samples fitted to GR metrics.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Barplot of estimated ED20 of simulated samples.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Barplot of estimated ED20 of simulated samples.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Reagents used for preparation of IntestiCult.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics
Reagents used for preparation of IntestiCult.